« Previous
Seminars in Oncology
Volume 33
, Pages 33-36
, February 2006
Future Perspectives in the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
References
- Pathogenesis of cutaneous lymphomas . Semin Cutan Med Surg . 2000;19:78–86
- Sézary Syndrome’s T-cell clones display T helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta chain) . Blood . 1996;88:1383–1389
-
Pathogenesis of cutaneous T-cell lymphoma – Implications for the use of recombinant cytokines and photopheresis
.
Clin Exp Immunol
. 1997;107:16–20
(suppl 1)
- The role for interleukin-12 therapy of cutaneous T cell lymphoma . Ann N Y Acad Sci . 2001;941:177–184
- Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma . Ann Oncol . 2002;13:1799–1805
- Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides . Dermatology . 2003;207:116–118
- Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors . Arch Dermatol . 2004;140:1490–1495
- Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity . J Immunol . 1995;154:116–127
- IL-12 reverses cytokine and immune abnormalities in Sezary syndrome . J Immunol . 1995;154:1491–1498
- Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses . Blood . 1999;94:902–908
- Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas . Blood . 2004;104:1631–1638
- Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells (Relevance to mechanism of therapeutic action) . Clin Cancer Res . 2002;8:1234–1240
- . Retinoids (Therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma) . Dermatol Ther . 2003;16:322–330
- Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication . Blood . 2001;97:523–527
- Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome (Correlation of activity and interleukin-2 receptor expression in a phase II study) . Blood . 1994;84:1765–1774
- Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma . J Clin Oncol . 2001;19:376–388
- Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells . J Invest Dermatol . 2001;117:583–589
- Gateways for clinical trials . Methods Find Exp Clin Pharmacol . 2004;26:357–391
- . Emerging drugs in cutaneous T-cell lymphomas . Expert Opin Emerg Drugs . 2005;10:381–392
This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.
Prof Dummer has participated in scientific symposia and advisory boards sponsored by Zeneus and Ligand Pharma.
PII: S0093-7754(05)00515-4
doi: 10.1053/j.seminoncol.2005.12.021
© 2006 Elsevier Inc. All rights reserved.
« Previous
Seminars in Oncology
Volume 33
, Pages 33-36
, February 2006
